Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
NCT03114527Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Aug 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib and everolimus in dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Antitumor activity of Ribociclib in combination with Everolimus at 16 weeks. Started Aug 2017; status: active, not recruiting.
02
Drugs
ribociclibeverolimus
03
Conditions
dedifferentiated liposarcoma (DDL)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03114527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114527.